Davis Polk advised Royalty Pharma plc on the transaction.Royalty Pharma executed its offering of $1.3 billion aggregate principal amount of senior notes. The offering consisted of $600…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
